Becton, Dickinson and Company (BDX) Shares Bought by Cooke & Bieler LP

Cooke & Bieler LP boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 18.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 353,807 shares of the medical instruments supplier’s stock after acquiring an additional 55,733 shares during the period. Cooke & Bieler LP owned 0.17% of Becton, Dickinson and worth $69,032,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. raised its stake in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares during the period. Vanguard Group Inc. grew its holdings in Becton, Dickinson and by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Becton, Dickinson and by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares in the last quarter. Fundsmith LLP grew its holdings in Becton, Dickinson and by 3.2% in the 1st quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after buying an additional 71,691 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Becton, Dickinson and by 8.4% in the 1st quarter. Geode Capital Management LLC now owns 1,941,743 shares of the medical instruments supplier’s stock valued at $355,653,000 after buying an additional 151,238 shares in the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

BDX has been the topic of a number of research reports. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $196.93.

Shares of Becton, Dickinson and Company (BDX) opened at 193.00 on Wednesday. The stock’s 50 day moving average price is $199.01 and its 200 day moving average price is $191.58. The firm has a market capitalization of $43.92 billion, a price-to-earnings ratio of 55.89 and a beta of 1.06. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.35 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

In other news, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/09/20/becton-dickinson-and-company-bdx-shares-bought-by-cooke-bieler-lp.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply